Abstract
Endocrine therapy plays a central role of systemic treatment for breast cancer. Luteinizing hormone-releasing hormone (LHRH) agonist, such as goserelin or leuprorelin is effective to premenopausal hormone-receptor positive breast cancer through medical ovarian ablation. Both slowly releasing agents are administered by subcutaneous injection with an interval of one or three months.
Fulvestrant, a pure antiestrogen, that is intramuscularly given every 4 weeks, is active against tamoxifen or aromatase-inhibitor resistant breast cancer. Nanoparticle conjugated with tamoxifen or LHRH agonist may enhance antitumor activity.
